Sequella Home Page

Latest News

Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the
Treatment of Multidrug-Resistant Pulmonary Tuberculosis

Sequella Acquires Exclusive Worldwide Rights to Pfizer's Sutezolid, Currently in Clinical Development for Tuberculosis

Sequella's Lead Antitubercular Drug Candidate SQ109 Begins Phase 2b Clinical Trial in Africa

Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed from Sequella

LabCorp Enters Into License Agreement with Sequella for use of B-SMART™ Technology to develop Rapid Tuberculosis Antimicrobial Susceptibility Test

Welcome to Sequella


Sequella is a clinical-stage pharma company that develops new and better antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company's product portfolio addresses devastating global health threats that affect over 3 billion people worldwide:

Mycobacterium tuberculosis: Products in our pipeline address tuberculosis (TB), multidrug-resistant TB (MDR-TB), and extremely drug-resistant TB (XDR-TB), diseases that affect 2.3 billion people, causing 10 million active infections and killing 2 million people yearly. Two of our drug candidates have completed phase 2 clinical trials (SQ109, sutezolid), one drug candidate (SQ609) is in preclinical development.

Helicobacter pylori: infections of the stomach that affect 3 billion people worldwide and cause gastric and duodenal ulcers and facilitate the development of gastric cancer. SQ109 demonstrated the ability to reduce a biomarker  in H. pylori infections in a proof-of-principle clinical trial in patients.

Clostridium difficile: hospital-based and community-acquired infection that can cause life-threatening diarrhea and is currently the #1 health threat in the U.S. (400,000 infections and 20,000 deaths yearly). SQ641 is a preclinical stage drug candidate for this indication.

Nontuberculous mycobacteria: infections responsible for pneumonias, Buruli ulcer, and Crohn's disease. SQ641 is a preclinical stage drug candidate for these indications.

Trypanosomes: Parasitic infections affect more than 12 million people annually. SQ109 and analogues demonstrated activity against Leishmania sp. and Trypanosoma cruzi parasites in vitro.


Fungal Infections: Sequella’s chemical compound library and pipeline of drug candidates include a number of compounds with activity on one or more of the most prevalent fungal infections in the U.S. and elsewhere.


Please see our Executive Summary for more information on the company and our products.